News >

Emerging Trastuzumab Biosimilar May Promote Competition

Angelica Welch
Published: Tuesday, May 22, 2018

Dr. Elisavet Paplomata
Elisavet Paplomata, MD
Multiple trastuzumab (Herceptin) biosimilars are currently being developed in the United States. In the wake of the December 2017 approval of MYL-1401O (Ogivri; trastuzumab-dkst), Elisavet Paplomata, MD, believes that ABP 980 may be the next trastuzumab biosimilar to make it through the regulatory process in both the United States and Europe.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for the marketing authorization of ABP 980 in March 2018 based on data from the phase III LILAC study. This study compared neoadjuvant paclitaxel plus ABP 980 with neoadjuvant paclitaxel plus trastuzumab.

Findings from the LILAC trial showed that in women with HER2-positive early breast cancer, 47.8% of patients in the ABP 980 arm (n = 364) and 41.8% in trastuzumab arm (n = 361) achieved pathologic complete response (pCR), according to central independent review. Risk difference of pCR was 5.8% (90% CI, -0.5 to 12.0) and risk ratio of pCR was 1.14 (90% CI, 0.993-1.312).

Amgen and Allergan, the developers of ABP 980, also submitted a biologics license application for the biosimilar to the FDA in 2017.

The approval of this biosimilar would create competition with both the original biologic and MYL-1401O, which could drive down costs, said Paplomata. Additionally, international approval of this biosimilar could allow low-income countries to access treatment for their patients with HER2-positive breast cancer.

In an interview with OncLive, Paplomata, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, discussed ABP 980 and the impact that biosimilars may have on global access to cancer care.

OncLive: There are multiple trastuzumab biosimilars in development, and one is approved in the United States. Can you provide insight on this evolving area?

Paplomata: Biosimilars are different than generic drugs, which we are all very familiar with. Generic drugs are structurally the same drug as the parent drug. A biosimilar is a biologic product which may have a similar but different structure from the reference product, but has shown in phase III trials to have the same efficacy and safety.

The FDA has a specific process of approving [these types of] drugs. Of course, they are cheaper than the parent drug to develop because they do not require all of the clinical trials that trastuzumab had to go through to be approved for all the indications. If a trial of a biosimilar shows the same efficacy as a reference product, it can be approved for all the same indications. 

There are multiple biosimilars in development right now. The biosimilar industry did not start in oncology, but in inflammatory disorders like rheumatoid arthritis. Biosimilars have been used for several years in Europe. Even though we have not used biosimilars as anticancer therapy, we as oncologists have experience with another biosimilar—filgrastim-sndz (Zarxio), which is a biosimilar of filgrastim (Neupogen). That was approved in 2015, and we have used it for about 1 year now.

Some payers favor Zarxio, as it is about 15% cheaper than the parent drug. Many oncologists have encountered this in their practice. In this case, we inform the patient that we will use the specific drug instead based on their insurance coverage and we proceed with this alternative therapy. The efficacy and side effect profile are similar. My understanding is that Zarxio has not really changed the US growth factor market significantly. However, that may be because it is the only biosimilar in the market, thus there is not much competition. 

One biosimilar for trastuzumab has already been FDA approved. That was done in December 2017, when I was in the middle of writing the paper for APB 980. MYL-1401O was approved by the FDA but is not out on the market yet. Typically, any drug that is approved by the FDA takes a few months to get out to the market. With biosimilars, it might be even a longer process. I am not sure when these drugs are going to be available to give to these patients. I understand that a biosimilar for bevacizumab (Avastin) was approved several months before MYL-1401O, and it is not out on the market yet. There are several legal issues that I am not familiar with. 

In our article, we focused on all the biosimilars to trastuzumab with ABP 980. This is a medication developed with Allergen and Amgen. The LILAC trial compared ABP 980 with trastuzumab, and that was a phase III trial showing that ABP 980 had similar efficacy to trastuzumab. LILAC randomized patients to neoadjuvant ABP 980 with paclitaxel versus trastuzumab and paclitaxel. It is in good standing to possibly be approved in the future by the FDA and Europe, as well. In this area, Europe seems to be a little ahead. Many European countries are invested into lowering healthcare costs. We are trying to limit healthcare costs, and I believe having biosimilars will help limit healthcare costs. 


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
Community Practice Connections™: Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic MalignanciesMar 08, 20193.0
Publication Bottom Border
Border Publication
x